Expanding the chemistry of life is an essential component in synthetic biology.^[@ref1]−[@ref4]^ Dominant among frontier applications is the site-specific incorporation of nonstandard amino acids (NSAAs) into proteins. Introducing NSAAs engenders proteins with new functional and structural features that are not possible with the canonical 20 amino acid building blocks.^[@ref5]^ For example, proteins with unique chemical handles for precise conjugation can be generated to enable next generation antibody-drug conjugate therapeutics.^[@ref6]^ In another exemplary illustration, incorporating a uniquely reactive NSAA for site-specific conjugation of polyethylene glycol resulted in a modified human growth hormone with increased potency and reduced injection frequency.^[@ref7]^ Furthermore, recent breakthroughs showing the direct synthesis of phosphoproteins^[@ref8]^ and selenoproteins^[@ref9]^ showcase the utility of NSAA incorporation. To date, more than 70 NSAAs have been site-specifically incorporated into proteins in *Escherichia coli*, yeast, and mammalian cells.^[@ref5]^ To achieve this, orthogonal suppressor tRNA (o-tRNA)/aminoacyl-tRNA synthetase (aaRS) pairs as well as ribosomes have been evolved to reinterpret the genetic code in response to nonsense or quadruplet codons.^[@ref10],[@ref11]^ Importantly, these o-tRNA/aaRS pairs are designed to operate parallel to and independent of the cell's endogenous machinery.

To expand the genetic lexicon, the amber (TAG) stop codon, one of three nonsense codons, is typically reprogrammed as a sense codon for the incorporation of NSAAs. This is called amber suppression.^[@ref4]^ An engineered tRNA~CUA~^Tyr^/TyrRS pair derived from *Methanocaldococcus jannaschii* has been used most extensively to incorporate NSAAs in response to the amber codon in *E. coli*.^[@ref4]^ More recent demonstrations of the technology have used variants of the pyrrolysine system, tRNA~CUA~^Pyl^/PylRS from *Methanosarcinaceae* species,^[@ref12]^ which naturally recognizes the nonsense amber codon.^[@ref4]^ A challenge for amber suppression is the fact that evolved o-tRNAs must outcompete the endogenous release factor 1 (RF1). It is known that the presence of RF1 can result in the production of truncated proteins, particularly when multiple site-specific incorporations are desired, resulting in low yields of the target protein product.^[@ref8]^ To address this limitation, recent studies have sought to create RF1 deletion strains. In one approach, RF1 deletion was enabled by creating gain of function mutations in release factor 2 that allow it to recognize the TAG stop signal.^[@ref13]^ In another approach, efforts to reassign the TAG codon to the TAA synonym can enable RF1 deletion. This was initially achieved for seven essential genes using a bacterial artificial chromosome.^[@ref14]^ More recently, precise chromosome manipulation *in vivo* is enabling genomically recoded organisms (GROs) with TAG nonsense codons reassigned. These efforts have shown utility for improving suppression efficiency for site-specific NSAA incorporation *in vivo*.

*In vitro* (or cell-free) protein synthesis (CFPS) is emerging as a powerful technology platform for site-specific incorporation of NSAAs.^[@ref1],[@ref15],[@ref16]^ The driving force behind this recent growth is 3-fold. First, a technical renaissance has enabled high-yielding (\>1 g/L) and long-lasting (\>10 h in batch operation) protein production.^[@ref15]^ Second, cost-effective energy generation systems by mimicking the *E. coli* cytoplasmic environment^[@ref17],[@ref18]^ and optimization of extract activity, codon usage, and redox folding conditions have enabled microscale to manufacturing scale (100 L), achieving linear scalability over a 6 orders of magnitude range in volume.^[@ref19]^ These developments are covered in detail in two recent reviews.^[@ref15],[@ref20]^ Third, the open nature of CFPS platform brings an unprecedented level of control and freedom of design compared to *in vivo* systems.^[@ref21]^ For example, new components (natural and non-natural) can be added or synthesized and can be maintained at precise ratios. In contrast to *in vivo* systems, there are no transport limitations for getting NSAAs into the cell and there is flexibility for reprogramming the genetic code because cellular viability need not be maintained, noting that this reprogramming must not significantly affect the ability of the organism to grow and provide the necessary components for CFPS using bacterial extract. To this point, a benefit is that not all components necessary for genetic reprogramming need to be produced in the same strain. For example, the open nature of CFPS could address growth problems by adding purified orthogonal synthetase into the reaction and enabling *in situ* expression of orthogonal tRNA.^[@ref22]^

Over the past decade, several groups have demonstrated the power of using crude extract CFPS systems for site-specific incorporation of NSAAs. In one exemplary illustration, Albayrak and Swartz demonstrated a modular and efficient cell-free platform that yields up to 0.9--1.7 mg/mL of a modified (*i.e*., containing a NSAA) soluble superfolder green fluorescent protein (sfGFP) in which the o-tRNA and the modified protein are produced simultaneously.^[@ref22]^ Notably, CFPS yields were higher than comparative studies *in vivo*.^[@ref22]^ Other examples include efforts to (i) leverage cell-free systems to avoid solubility and transport limitations typically encountered *in vivo* in the incorporation of the tyrosine analog *p*-propargyloxy-[l]{.smallcaps}-phenylalanine (pPaF) as well as *p*-azido-[l]{.smallcaps}-phenylalanine for demonstrating a one-step, site-specific direct protein--protein conjugation using copper(I)-catalyzed azide--alkyne \[3 + 2\] cycloaddition,^[@ref23],[@ref24]^ (ii) explore drug discovery by site-specific tagging with NSAA,^[@ref25]^ and (iii) enhance enzyme activity through NSAAs otherwise difficult with natural amino acids.^[@ref26]^

Despite the fact that CFPS expression systems offer advantages and open new opportunities for NSAA incorporation,^[@ref27]^ competition between RF1 in the extract and o-tRNAs remains a limitation.^[@ref22]^ RF1-deficient CFPS systems have been constructed by removing RF1 tagged with chitin-binding domains^[@ref28]^ and by using an RF1-deleted strain enabled by reassigning seven amber codons to their synonymous TAA.^[@ref29]^ However, extracts from GROs lacking RF1 have not been attempted.

In this article, we describe the development of a CFPS platform from a genomically recoded *E. coli* strain lacking RF1 (encoded by *prfA)*, called *rEc.E13.ΔprfA*.^[@ref30]^ The goal was to characterize suppression efficiency in the presence and absence of RF1 and assess the ability to introduce NSAAs, pPaF or *p*-acetyl-[l]{.smallcaps}-phenylalanine (pAcF), at single and multiple sites (Figure [1](#fig1){ref-type="fig"}). For characterization purposes, we further compared our S30 crude extract based CFPS platform to the PURE ([P]{.ul}rotein synthesis [U]{.ul}sing [R]{.ul}ecombinant [E]{.ul}lements) translation system^[@ref31]^ lacking RF1. In both the PURE system and extract based CFPS approach, we demonstrate that removal of RF1 increases the amount of full-length modified NSAA-containing protein more than 250%, providing benefits for incorporating NSAA at multiple in-frame positions.

![Scheme of cell-free protein synthesis reaction incorporating nonstandard amino acid to investigate the effect of RF1. Cell extracts containing transcription and translation machinery are prepared from *rEc.E13* or *rEc.E13.ΔprfA* strains. Plasmid DNA template of sfGFP containing single or multiple amber codon sites, orthogonal tRNA/aaRS, NSAA, T7 RNA polymerase, and other cofactors are added as necessary to activate the cell-free protein synthesis (CFPS) reaction.](sb-2013-00140t_0002){#fig1}

Results and Discussion {#sec2}
======================

*rEc.E13.ΔprfA* as a Chassis Strain for CFPS {#sec2.1}
--------------------------------------------

In anticipation of completion of fully recoded GRO wherein all occurrences of the stop TAG codon are reassigned to the synonymous TAA codon, we created pilot strains having either seven essential genes (*coaD*,*had*,*hemA*,*mreC*,*murF*,*lolA*, and *lpxK*)^[@ref32]^ or these genes plus an additional six genes (*yafF*, *pgpA*, *sucB*, *fabH*, *fliN*, and *atpE)* recoded to create the strains *rEc.E7* or *rEc.E13*,^[@ref30]^ respectively. Next, we introduced the gene that confers resistance to spectinomycin (*spec*^*R*^) into the *prfA* locus to create RF1 knockout strains (*rEc.E7.ΔprfA* and *rEc.E13.ΔprfA*). While the *rEc.E7.ΔprfA* had a severe growth phenotype, the *rEc.E13.ΔprfA* grew nearly twice as fast, providing a suitable RF1 deletion chassis strain for this work. The TAG codon reassignment to TAA of the six additional genes in *rEc.E13.ΔprfA* strain might allow better fitness in the cell growth by alleviating natural suppression pressure.^[@ref30]^ The doubling time for *rEc.E13.ΔprfA* and the parent *rEc.E13* was 64.6 ± 0.9 min and 47 ± 2 min, respectively, in 2xYTPG media (Figure [2](#fig2){ref-type="fig"}), and in LB, 74.8 ± 1.2 min for *rEc.E13.ΔprfA* and 50.3 ± 0.7 min for *rEc.E13* ([Supporting Information Figure S1](#notes-2){ref-type="notes"}). The *rEc.E13.ΔprfA* chassis strain grows slower than the *rEc.E13* because there is only partial recoding of the genome.^[@ref30]^

![Growth rate comparison of *rEc.E13* and *rEc.E1.ΔprfA* strains. Growth of *rEc.E13* and *ΔprfA* in 2xYTPG medium at 34 °C in 96 well plates. Each data point is the average of ten replicate wells from two independent cultures.](sb-2013-00140t_0003){#fig2}

RF1 Deletion Enhances pPaF Incorporation in CFPS {#sec2.2}
------------------------------------------------

The impact of RF1 deletion on NSAA incorporation in CFPS reactions was assessed in S30 crude cell extract CFPS reactions. The o-tRNA was expressed constitutively under the control of *lpp* promoter in extract source strain during cell growth as described previously.^[@ref24]^ Following extract preparation, we used the PANOx-SP CFPS system developed by Jewett and Swartz^[@ref17]^ to quantitatively test the incorporation of pPaF into sfGFP with an in-frame amber codon at position 132 (sfGFP132pPaF). Initially, we carried out a series of optimization experiments in extracts from *rEc.E13* to examine the effects of temperature, incubation time, and pPaFRS concentrations on CFPS (Figure [3](#fig3){ref-type="fig"}). Combined transcription and translation reactions were carried out in 15 μL batch reactions. Figure [3](#fig3){ref-type="fig"}a shows wild-type sfGFP and sfGFP132pPaF synthesis at 30 and 37 °C throughout the batch reaction duration. For sfGFP132pPaF, we additionally added 0.5 mg/mL pPaFRS (see Figure [3](#fig3){ref-type="fig"}b for optimization) and 2 mM pPaF.^[@ref24]^ Active protein synthesis yields, as assessed by fluorescence, were approximately 2.5-fold higher at 30 °C for both wild-type and modified sfGFP. Our data are consistent with previous results, which have shown advantages for sfGFP folding^[@ref33]^ and NSAA incorporation^[@ref24]^ at 30 °C as compared to 37 °C. Because sfGFP synthesis was most productive in 20 h batch reactions at 30 °C, all further CFPS reactions were carried out using these conditions.

![Optimization of pPaF incorporation. (a) Time course sfGFP synthesis in extracts derived from *rEc.E13.ΔprfA* illustrates the effect of temperature on CFPS (pPaF = 2 mM, pPaFRS = 0.5 mg/mL, temperature = 30 and 37 °C for 20 h). Wild-type sfGFP (wt-sfGFP) was produced from pY71-sfGFP plasmid, modified sfGFP with pPaF at single amber site corresponding at E132 (sfGFP132pPaF) was produced from pY71-sfGFP-E132amb, and no plasmid was added as a control (no plasmid). (b) pPaF incorporation using pY71-sfGFP-E132amb plasmid with 0.1 to 2 mg/mL of pPaFRS at 2 mM pPaF. Each data point is the average of three independent reactions, and one standard deviation is shown.](sb-2013-00140t_0004){#fig3}

We next compared sfGFP132pPaF synthesis in extracts from *rEc.E13* with and without RF1 (*ΔprfA*) (Figure [4](#fig4){ref-type="fig"}, Table [1](#tbl1){ref-type="other"}). As a control, active wild-type sfGFP as assessed by fluorescence was synthesized at equivalent levels, indicating similar protein synthesis activity (Figure [4](#fig4){ref-type="fig"}a). Strikingly, extracts from *rEc.E13.ΔprfA* synthesized active sfGFP132pPaF yields more than 2.5-fold from 71 ± 6 μg/mL to 190 ± 20 μg/mL when compared to RF1-present *rEc.E13* extracts (suppression efficiency: 53% in the RF1-deficient vs 21% in the RF1-present) (Figure [4](#fig4){ref-type="fig"}a, Table [1](#tbl1){ref-type="other"}). This result highlights significant benefits for using RF1-deficient strains. Upon closer examination, we observed that much of this benefit is due to an increase in full-length modified sfGFP synthesis. Specifically, introduction of ^14^C-leucine into the CFPS reaction allowed us to use autoradiograms to show that the ratio of full-length to truncated form of sfGFP132pPaF in the absence of RF1 was ∼8:2 (Figure [4](#fig4){ref-type="fig"}b, Table [1](#tbl1){ref-type="other"}), whereas the ratio in the presence of RF1 was ∼2:8 (Figure [4](#fig4){ref-type="fig"}b, Table [1](#tbl1){ref-type="other"}). As a control, only full-length wild-type sfGFP was synthesized regardless of the presence or absence of RF1 (Figure [4](#fig4){ref-type="fig"}b). Total protein and soluble sfGFP synthesis yields quantified using ^14^C-leucine incorporation into trichloroacetic acid-precipitable radioactivity were consistent with the above analysis. When RF1 is present during protein biosynthesis, the o-tRNA competes with RF1^[@ref4]^ and in turn reduces the incorporation efficiency of NSAA. This results in the major portion of synthesized proteins being truncated (Figure [4](#fig4){ref-type="fig"}b, Table [1](#tbl1){ref-type="other"}). However, when RF1 is absent, the o-tRNA must only compete against natural suppression mechanisms,^[@ref34]^ and thereby the majority of protein produced with pPaF is full-length (Figure [4](#fig4){ref-type="fig"}b, Table [1](#tbl1){ref-type="other"}). Hence, our RF1-deficient CFPS system enhances incorporation of NSAA into a protein.

![Effect of RF1 deletion of production of sfGFP with single site pPaF incorporation. (a) sfGFP synthesis in the presence or absence of RF1 in cell-extract based CFPS system at 30 °C for 20 h. Wild-type sfGFP (wt-sfGFP) was produced from pY71-sfGFP plasmid, modified sfGFP with pPaF (sfGFP132pPaF) was produced from pY71-sfGFP-E132amb with 2 mM pPaF and 0.5 mg/mL pPaFRS, and no pPaFRS (sfGFP132amb/no pPaFRS) or pPaF (sfGFP132amb/no pPaF) was added. At least three independent reactions were performed for each sample, and one standard deviation is shown. (b) Autoradiogram of ^14^C-leucine labeled proteins. FL indicates full-length sfGFP (27.1 kDa), and TR indicates truncated sfGFP at E132 (14.8 kDa).](sb-2013-00140t_0005){#fig4}

###### Yield of Native and Modified Proteins[a](#tbl1-fn1){ref-type="table-fn"}

  protein                 total protein (μg/mL)[b](#t1fn1){ref-type="table-fn"}   soluble protein (μg/mL)[b](#t1fn1){ref-type="table-fn"}   active protein (μg/mL)[c](#t1fn2){ref-type="table-fn"}   suppression efficiency (%)[d](#t1fn3){ref-type="table-fn"}   full-length protein (%)[e](#t1fn4){ref-type="table-fn"}   truncated protein (%)[e](#t1fn4){ref-type="table-fn"}
  ----------------------- ------------------------------------------------------- --------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------ --------------------------------------------------------- -------------------------------------------------------
  RF1+                                                                                                                                                                                                                                                                                                                      
  wt-sfGFP                403 ± 2                                                 349 ± 9                                                   360 ± 40                                                                                                              100                                                       0
  sfGFP132pPaF            330 ± 20                                                236 ± 8                                                   71 ± 6                                                   21                                                           20                                                        80
  sfGFP132amb/no pPaFRS   330 ± 10                                                220 ± 20                                                  1.8 ± 0.4                                                1                                                            1                                                         99
  RF1--                                                                                                                                                                                                                                                                                                                     
  wt-sfGFP                348 ± 5                                                 320 ± 10                                                  360 ± 30                                                                                                              100                                                       0
  sfGFP132pPaF            282 ± 3                                                 270 ± 30                                                  190 ± 20                                                 53                                                           78                                                        22
  sfGFP132amb/no pPaFRS   252 ± 6                                                 220 ± 4                                                   37 ± 5                                                   11                                                           32                                                        68

The extract-based CFPS reaction was performed at 30 °C for 20 h.

Total and soluble protein yields were calculated from liquid scintillation counting of TCA precipitated radioactive ^14^C-labeled protein. Soluble proteins were obtained from the supernatant of the CFPS samples after centrifugation.

Active protein yield was calculated by measuring fluorescence.

Suppression efficiency is the ratio of the active modified protein yields to the active native protein.

Percentages of full-length and truncated proteins were determined by the densitometry of protein bands in autoradiogram.

RF1-Deficient CFPS System Increases pPaF Incorporation at Multiple Sites {#sec2.3}
------------------------------------------------------------------------

We next assessed the impact of RF1-deficient extracts on the incorporation of pPaF at multiple different sites in sfGFP. For these experiments, we built sfGFP constructs with 1, 2, 5, and 10 amber sites in loop regions (Figure [5](#fig5){ref-type="fig"}a), so as to avoid deleteriously impacting fluorescence.^[@ref13]^ Then, we compared CFPS yields in the presence or absence of RF1 as determined by fluorescence. Consistent with *in vivo* NSAA incorporation data,^[@ref13]^ we observed that increasing the number of amber incorporation sites decreased the sfGFP yield, regardless of the presence or absence of RF1 (Figure [5](#fig5){ref-type="fig"}b). Yields of sfGFP with E132, N212, or T216 replaced by pPaF (single site NSAA incorporation) were two to 6-fold higher in the absence of RF1 (Figure [5](#fig5){ref-type="fig"}b). In addition, multiple site incorporations were much more efficient in the absence of RF1; we observed a 10-fold increase in the modified protein yield with two incorporation sites and a 12-fold increase with five incorporation sites (Figure [5](#fig5){ref-type="fig"}b). For constructs with 10 TAG replacements, fluorescent protein was not detected (Figure [5](#fig5){ref-type="fig"}b). Taken together, our results highlight the critical importance of RF1-deficient extracts for synthesizing proteins bearing NSAAs at single as well as multiple different sites.

![Multiple site pPaF incorporation is enabled by RF1 deletion extracts and improved by *in situ* o-tRNA synthesis. (a) pPaF incorporation sites are shown in sfGFP using Pymol. Single site incorporation was performed with amber codons at positions E132, N212, and T216, two site incorporation at N212 and T216, five site incorporation at D36, K101, E132, D190, and E213, and ten site incorporation at D36, K101, D102, E132, D133, K140, D190, V193, E213, and D218. (b) sfGFP synthesis with single and multiple site pPaF incorporation in the presence or absence of RF1 with or without optimized o-tRNA (o-tRNA^opt^) at 30 °C for 20 h with 2 mM pPaF and 0.5 mg/mL pPaFRS. (c) Linear DNA templates for producing different types of o-tRNAs under the control of T7-promoter. In order to create transzyme, hammerhead ribozyme sequence was added between T7 promoter and o-tRNA sequence. Sequence differences between o-tRNA^opt^ and o-tRNA are shown in red nucleotides. (d) pPaF incorporation with different types of o-tRNAs (10 ng/μL) to synthesize sfGFP132pPaF using BL21(DE3) extract with 2 mM pPaF and 0.5 mg/mL pPaFRS. (e) Optimization of DNA concentration of transzyme o-tRNA^opt^ in pPa incorporation using BL21(DE3) extract. At least three independent reactions were performed for each sample, and one standard deviation is shown for parts b, d, and e.](sb-2013-00140t_0006){#fig5}

*In situ* Synthesis of Optimized o-tRNA Enhances pPaF Incorporation {#sec2.4}
-------------------------------------------------------------------

Previously, it has been shown that o-tRNA concentration in CFPS is limiting for NSAA incorporation.^[@ref24]^ To address this issue, Albayrak and Swartz recently developed a novel approach for *in situ* synthesis of the o-tRNA in the reaction, which significantly improves suppression efficiency.^[@ref22]^ Their key advance was the direct addition of a transzyme construct to the reaction mixture. In this construct, the hammerhead ribozyme was fused to o-tRNA. Once synthesized, the transzyme cleaves itself liberating active o-tRNA (*i.e*., 5′--OH tRNA transcript starting with the proper nucleotide).^[@ref35]^ To test the impact of the transzyme approach in our system, we constructed linear o-tRNA templates by PCR amplification with or without hammerhead ribozyme for the original o-tRNA^[@ref24]^ and an optimized o-tRNA (o-tRNA^opt^) that was evolved to enhance the efficiency of NSAA incorporation *in vivo*([@ref35],[@ref36]) (Figure [5](#fig5){ref-type="fig"}c). To protect possible degradation of linear DNA template for the o-tRNA, 500 bp of sequence upstream of the T7 promoter was added during amplification (Figure [5](#fig5){ref-type="fig"}c). After generation of the PCR amplicons, we examined modified protein synthesis with pPaF by cotranscribing o-tRNA or o-tRNA^opt^ and sfGFP from the linear DNA template and the plasmid, respectively.

To prove that the transzyme construct was functionally active, we first used BL21(DE3) cell extract that does not contain any o-tRNA. Transzymes of o-tRNA and o-tRNA^opt^ enabled the synthesis of the modified protein, while nontranszymes did not make the modified protein (Figure [5](#fig5){ref-type="fig"}d) due to a lack of active tRNA formation without correct cleavage after transcription.^[@ref35]^ As a control, the modified protein was not produced when no DNA template for o-tRNA or o-tRNA^opt^ was added (Figure [5](#fig5){ref-type="fig"}d). In addition, o-tRNA^opt^ resulted in more protein yield than the original o-tRNA (Figure [5](#fig5){ref-type="fig"}d), which is consistent with a previous report^[@ref36]^ and the fact that the o-tRNA^opt^ is a better suppressor tRNA than the original o-tRNA when in competition with translation termination by RF1. We further showed that modified sfGFP yield could be increased by increasing the amount of the linear DNA encoding the transzyme o-tRNA^opt^ up to 10 ng/μL (Figure [5](#fig5){ref-type="fig"}e).

We then used transzyme o-tRNA^opt^ in single and multiple site pPaF incorporation in the *rEc.E13* extracts with or without RF1 to measure if extra o-tRNA^opt^ increases the modified sfGFP yield. Indeed, the addition of 10 ng/μL o-tRNA^opt^ DNA template to CFPS reactions increased pPaF incorporation into sfGFP in the presence of RF1, having a more pronounced effect on multiple site incorporation (Figure [5](#fig5){ref-type="fig"}b). In RF1-deficient extracts, *in situ* o-tRNA^opt^ synthesis resulted in a 2-fold higher yield in modified protein synthesis with two and five incorporation sites, although it did not show increased protein yield at single site incorporations in the absence of RF1 (Figure [5](#fig5){ref-type="fig"}b). Our results suggest that o-tRNA concentrations are limiting in RF1-deficient extracts only for multisite incorporations. More broadly, our results highlight efficiency advantages with RF1-deficient extracts for incorporating multiple NSAAs into the same polypeptide. Another possibility is that there is competition with natural suppressors, which we discuss in detail below.

Quantitative Mass Spectrometry Data Discovers High Suppression Efficiencies for RF1-Deficient Extracts {#sec2.5}
------------------------------------------------------------------------------------------------------

While synthesis of sfGFP132pPaF is increased more than 2.5-fold in RF1-deficient extracts, we curiously observed a significant increase in the amount of active sfGFP synthesized in the absence of pPaFRS or pPaF in RF1-deficient extracts (Figure [4](#fig4){ref-type="fig"}a). These data imply mis-incorporation in the absence of RF1 when components of the orthogonal translation system are not added, which has also been observed *in vivo* in an RF1-deletion strain.^[@ref37]^ It is known that the ribosome can stall due to incomplete mRNA,^[@ref38]^ rare codons,^[@ref38]^ and at specific peptide sequences.^[@ref39]^ To bypass this issue, natural suppressor mechanisms exist to rescue ribosomes^[@ref34]^ (*e.g.,* SsrA-mediated peptide tagging^[@ref40]^) or noncognate tRNA interactions can install an incorrect amino acid, the latter of which we hypothesized was occurring in our system. This is because in the absence of both RF1 and a component of the orthogonal translation system (*e.g*., pPaF), the ribosome is expected to stall at in-frame amber codons. If this occurs, a canonical amino acid may be mis-incorporated to rescue the stalled ribosome. Previous studies reported that tyrosine,^[@ref36],[@ref37]^ phenylalanine,^[@ref36]^ tryptophan,^[@ref37]^ and glutamine^[@ref8],[@ref37],[@ref41]^ are misincorporated at amber codon. In addition, our previous *in vivo* work has shown direct genetic, Western blot, and mass spectrometry evidence for different types of natural mechanisms in the *rEc.E13.ΔprfA* strain.^[@ref30]^

We therefore used top-down (TD) mass spectrometry (*i.e*., MS analysis of intact proteins) to detect and provide semiquantitative information on the incorporation of pPaF into sfGFP. In typical proteomic workflows involving enzymatic digestion, truncations and mis-incorporated amino acid residues are difficult to detect, since information on intact protein length and sequence is lost. The TD methodology used here not only provides confirmation of single amino acid incorporation but is also capable of identifying truncations and mis-incorporation events at the same time. Specifically, intact sfGFP generated by CFPS was analyzed by nanocapillary LC-MS without prior sample purification. We observed that, for the samples without pPaFRS, glutamic acid (E) was incorporated at amber codon corresponding to position at E132 ([Supporting Information Figure S2a](#notes-2){ref-type="notes"}) and N212 of sfGFP ([Supporting Information Figure S2b](#notes-2){ref-type="notes"}). The CFPS reaction contains more than 150 mM glutamate as it is used as the dominant anion in the system. Thus, it appears that this high concentration relative to the other amino acids (2 mM) as well as the fact that the near cognate GAG codon assigned to glutamic acid tRNA^Glu^ is only a single bp different from the TAG amber codon allows for the natural suppression of the amber codon.

The above results could suggest that we additionally observe mis-incorporation when the entire orthogonal translation system is present when RF1 is absent. However, this is not the case. In the presence of all units of the orthogonal translation, NSAA incorporation is the major driving force of translation for amber codon suppression. Indeed, pPaF was correctly incorporated approximately 99% in sfGFP216pPaF (Figure [6](#fig6){ref-type="fig"}a) and more than 90% of the time in sfGFP132pPaF ([Supporting Information Figure S2a](#notes-2){ref-type="notes"}). Hence, the presence of all orthogonal translation components promotes site-specific NSAA incorporation by outcompeting natural suppression mechanisms. We also analyzed site-specific pPaF incorporation at two amber sites in sfGFP (sfGFP212pPaF216pPaF). We did not observe any mis-incorporation (Figure [6](#fig6){ref-type="fig"}b).

![Mass spectrometry analysis of pPaF incorporation at single and multiple amber sites in sfGFP shows high NSAA incorporation in RF1 deletion extracts. (a) pPaF incorporation was examined to the single amber site corresponding to the position of T216, (b) the two amber site corresponding to the positions of N212 and T216, and (c) the five amber site corresponding to the positions of D36, K101, E132, D190, and E213. Theoretical modified protein peaks of multiple site pPaF incorporation are shown.](sb-2013-00140t_0007){#fig6}

We further analyzed site-specific pPaF incorporation at five different amber sites per sfGFP (Figure [6](#fig6){ref-type="fig"}c). Increasing the number of pPaF incorporation sites decreased active protein synthesis yields (Figure [5](#fig5){ref-type="fig"}b). Likewise, correct pPaF incorporation efficiency to the multiple amber sites was decreased. There are 32 possible combinations with five incorporation sites in pPaF incorporation. We observed that less than 10% of the protein contained pPaF-incorporated at all five positions (D36, K101, E132, D190, and E213). The remaining 90% included various modified proteins with different numbers of pPaF incorporated (Figure [6](#fig6){ref-type="fig"}c).

We next asked if we observed a positional dependence of nonsense suppression efficiency in extracts from the RF1-deletion strain. Previously it has been shown that the specific location of an amber codon in the gene sequence has an impact in total protein yield and suppression efficiency.^[@ref22]^ Given the complexity of our data when trying to incorporate five NSAAs per sfGFP, we chose to focus on only single and double pPaF incorporation. When we altered the amber position, we observed a significant positional effect. For example, only half of the modified protein sfGFP212pPaF contained the correct pPaF incorporation, whereas the other half of the protein was mis-incorporation of E ([Supporting Information Figure S2b](#notes-2){ref-type="notes"}). In the case of sfGFP132pPaF190pPaF, approximately 20% of the modified sfGFP comprised pPaF-incorporated at both sites, while 60% contained pPaF-incorporated at only one of two amber sites (data not shown). Taken together, our mass spectrometry data highlight that extracts from RF1 deletion extracts provide advantages for site-specific NSAA incorporation. However, further strategies will be necessary to avoid natural suppression efficiencies, with one obvious step being the completion of a completed recoded organism.^[@ref30]^

pPaF Incorporation in PURE System {#sec2.6}
---------------------------------

We next studied the effect of RF1 on pPaF incorporation in PURE translation system^[@ref31]^ by adding 2 mM pPaF, 0.5 mg/mL pPaFRS, and 4.5 ng/μL linear DNA for o-tRNA^opt^. Corroborating the results in our extract-based system, the yield of the modified sfGFP with pPaF in the absence of RF1 was increased as compared to the system in the presence of RF1 in PURE CFPS (41 ± 3 μg/mL vs 19 ± 4 μg/mL, respectively). We subsequently confirmed by autoradiography that this was due to fewer truncated products in the absence of RF1 (Figure [7](#fig7){ref-type="fig"}a). Furthermore, we tested the effect of RF1 by adding different amount of RF1 in PURE reaction. As the amount of RF1 is increased, production of full-length modified sfGFP132pPaF was decreased, and the truncated protein was increased (Figure [7](#fig7){ref-type="fig"}b). Thus, the presence of RF1 inhibits NSAA incorporation in response to amber codon, and RF1 may be removed to improve protein synthesis yield containing NSAA. We directly compared our crude S30 extract system to the PURE translation system lacking RF1 in terms of the modified protein synthesis yield and the production cost. We observed that our S30 extract based approach produces about 5 times more protein (190 ± 20 μg/mL in extract based CFPS vs 41 ± 3 μg/mL in PURE) and is more cost-effective (less than \$0.05/reaction in extract based CFPS vs more than \$10.00/reaction in PURE) than the PURE translation system lacking RF1.

![pPaF incorporation in the PURE translation system. (a) Autoradiogram of radioactive labeled proteins. Wild-type sfGFP was produced from pY71-sfGFP plasmid, modified sfGFP was produced from pY71-sfGFP-E132amb with or without pPaFRS in the presence of pPaF. (b) Effect of RF1 concentration in pPaF incorporation. RF1 was diluted to ^1^/~8~, ^1^/~4~, and ^1^/~2~ of the amount that manufacturer suggested. FL indicates full-length sfGFP (27.1 kDa), and TR indicates truncated sfGFP at E132 (14.8 kDa).](sb-2013-00140t_0008){#fig7}

pAcF Incorporation {#sec2.7}
------------------

To demonstrate the benefit of RF1-deficient extracts for CFPS more broadly, we extended our approach to another NSAA, namely pAcF. pAcF serves as a bio-orthogonal handle and has recently been incorporated into proteins and functionalized to engender more potent and stable human growth hormone^[@ref7]^ and to improve the activity of antibody-drug conjugates.^[@ref6]^ The suppressor o-tRNA used for pPaF incorporation is compatible to pAcF.^[@ref36]^ Thus, we used same cell-extract with the addition of pAcF and pAcFRS to examine pAcF incorporation. Based on the final yield of modified sfGFP after a 20 h CFPS reaction, pAcF incorporation at a single site (sfGFP132pAcF) was about 20% higher in RF1-deficient extracts (Figure [8](#fig8){ref-type="fig"}). While the overall % increase was lower than pPaF, our data consistently show that removing RF1 is beneficial for CFPS of proteins containing NSAAs.

![pAcF incorporation. sfGFP synthesis with pAcF (2 mM) and pAcFRS (0.5 mg/mL) in the presence or absence of RF1 in CFPS system at 30 °C for 20 h. Wild-type sfGFP (wt-sfGFP) was produced from pY71-sfGFP plasmid; modified sfGFP with pAcF (sfGFP132pAcF) was produced from pY71-sfGFP-E132amb; and no pAcFRS was added (sfGFP132amb/no pAcFRS). Three independent reactions were performed for each sample, and one standard deviation is shown.](sb-2013-00140t_0009){#fig8}

Genetic code expansion is a promising means in protein engineering to develop new functional and structural biomolecules.^[@ref5]^ In this study, we utilized CFPS to systematically examine NSAA incorporation in response to the amber codon in cell-free translation systems lacking RF1. We showed that omitting RF1 enhances NSAA incorporation at single site, as well as multiple different sites, in a single protein. Moreover, RF1 deletion enables a significant shift from truncated to full-length product, which provides advantages over previously reported systems. Furthermore, we were able to easily modulate components of the orthogonal translation system to levels that might otherwise be toxic to cells in order to maximize NSAA incorporation. The production of orthogonal components often causes impaired cellular fitness *in vivo*. For example, we observed impairment of cell growth upon maximizing pPaFRS or pAcFRS overproduction ([Supporting Information Figure S3a and b](#notes-2){ref-type="notes"}). This fitness impairment can be avoided using CFPS technologies.^[@ref23]^

Although we show that deleting RF1 is critical to enhance NSAA incorporation, the overall protein synthesis yields presented here are lower than those published recently by Albayrak and Swartz.^[@ref22]^ We hypothesize that this is because the strain used in that study had been subjected to more than a decade of strain engineering efforts to stabilize reaction substrates. Indeed it is well-known that strain modification is a powerful tool for increasing CFPS yields.^[@ref15]^ For example, stabilization of amino acid substrates by deleting genes related to substrate depletion,^[@ref42]^ stabilization of DNA by deleting genes encoding endonuclease I,^[@ref43]^ and reduction of protein degradation by disrupting proteases^[@ref44]^ enabled high-yield protein synthesis in CFPS systems. In addition to eliminating deleterious pathways, activating beneficial pathways may improve protein production, as shown that adding elongation factors to CFPS reactions increased protein synthesis rates and yields.^[@ref45]^ Because the parent *rEc.E13.ΔprfA* strain has not been previously optimized for CFPS, we expect that future efforts to design and construct synthetic genomes that upon cell lysis lead to improved extract performance will increase synthesis yields of proteins bearing NSAAs. For example, multiplex automated genome engineering (MAGE)^[@ref46]^ could be used to make numerous genomic changes upregulating positive effectors and downregulating negative effectors both individually and in combinations insofar as these genomic changes do not have a deleterious effect on the growth of the organism.

Looking forward, additional strain engineering efforts could also be pursued to reduce and remove natural suppression mechanisms. As described above, in the absence of some orthogonal translation components, we observe glutamate incorporation at the amber codon in RF1 deficient extracts from a partially recoded strain (13 of 321 amber sites in the genome). We hypothesize this phenotype is caused by the fact that the strain lacking RF1 induces natural suppression mechanisms during cell growth prior to extract generation to help deal with ribosomal pausing at amber sites present in the genome. Replacing the remaining amber codons in the genomes (*i.e.*, the fully recoded *E. coli* strain) should reduce natural suppression mechanisms, as was observed *in vivo*.^[@ref30]^

In summary, we described a novel CFPS platform derived from the RF1-deficient strain *rEc.E13.ΔprfA* with advantages for improved amber suppression. While it is still early in the development of crude extract based CFPS system derived from RF1 deficient strains, our advances, along with the potential for future strain engineering, suggest promise for future efforts to generate sequence-defined proteins or polymers with many NSAAs at high yields and purity. Indeed, we anticipate that RF1 deficient chassis strains will achieve greater than 1g/L yields in the upcoming years, becoming a significant player on the stage with other CFPS technologies for synthesis of unnatural biopolymers with high efficiency and high fidelity.

Methods {#sec3}
=======

Bacterial Strains and Plasmids {#sec3.1}
------------------------------

The bacterial strains and plasmids used in this study are listed in Table [2](#tbl2){ref-type="other"}. We used *rEc.E13* (a modified EcNR2 strain),^[@ref30]^*rEc.E13.ΔprfA*,^[@ref30]^ and BL21(DE3) strains for making S30 cell extract and BL21(DE3) for producing the orthogonal amino acyl tRNA synthetases. Chloramphenicol (25 μg/mL) was used for preculturing *rEc.E13*, spectinomycin (20 μg/mL) for preculturing *prfA* knockout mutant, and kanamycin (50 μg/mL), chloramphenicol (25 μg/mL), and tetracycline (20 μg/mL) for maintaining plasmids as necessary.

###### Strains and Plasmids Used in This Study[a](#tbl2-fn1){ref-type="table-fn"}

  strains and plasmids     genotype/relevant characteristics                                                                                                                                               source
  ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------
  Strains                                                                                                                                                                                                  
  *rEc.E13*                EcNR2^[@ref46]^ (Cm^R^, Ap^R^) with 13 TAG termination reassignments to TAA at *coaD*,*hda*,*hemA*,*mreC*,*murF*,*lolA*,*lpxK*,*yafF*,*pfpA*,*sucB*,*fabH*,*fliN*, and *atpE*   ([@ref30])
  *rEc.E13.ΔprfA*          *rEc.E13 ΔprfA* Ω Sp^R^                                                                                                                                                         ([@ref30])
  BL21(DE3)                *fhuA2 \[lon\] ompT gal (λ DE3) \[dcm\] ΔhsdS λ DE3 = λ sBamHIo ΔEcoRI-B int::(lacI::PlacUV5::T7 gene1) i21 Δnin5*                                                              New England Biolabs
  Plasmids                                                                                                                                                                                                 
  pY71-sfGFP               Km^R^, *P*~*T7*~*::sfGFP*, C-terminal Strep-tag                                                                                                                                 ([@ref24])
  pY71-sfGFP-E132amb       pY71-sfGFP with amber codon at E132                                                                                                                                             this study
  pY71-sfGFP-N212amb       pY71-sfGFP with amber codon at N212                                                                                                                                             this study
  pY71-sfGFP-T216amb       pY71-sfGFP with amber codon at T216                                                                                                                                             ([@ref24])
  pY71-sfGFP-2amb          pY71-sfGFP with amber codon at N212 and T216                                                                                                                                    this study
  pY71-sfGFP-5amb          pY71-sfGFP with amber codon at D36, K101, E132, D190, and E213                                                                                                                  this study
  pY71-sfGFP-10amb         pY71-sfGFP with amber codon at D36, K101, D102, E132, D133, K140, D190, V193, E213, and D218                                                                                    this study
  pY71-pPaFRS              Km^R^, *P*~*T7*~*::pPaFRS*, C-terminal 6x histidine tag                                                                                                                         ([@ref24])
  pEVOL-pAcF               Cm^R^, *P*~*glnS*~*::pAcFRS, P*~*araBAD*~*::pAcFRS, P*~*proK*~::o-tRNA^opt^                                                                                                     ([@ref36])
  pY71-pAcFRS              Km^R^, *P*~*T7*~*::pAcFRS*, C-terminal 6x histidine tag                                                                                                                         this study
  pDULE-o-tRNA             Tet^R^, *P*~*lpp*~::o-tRNA                                                                                                                                                      ([@ref24])
  pY71-T7-tz-o-tRNA        Km^R^, *P*~*T7*~:: transzyme o-tRNA                                                                                                                                             this study
  pY71-T7-tz-o-tRNA^opt^   Km^R^, *P*~*T7*~:: transzyme o-tRNA^opt^                                                                                                                                        this study
  pY71-T7-o-tRNA           Km^R^, *P*~*T7*~::o-tRNA                                                                                                                                                        this study
  pY71-T7-o-tRNA^opt^      Km^R^, *P*~*T7*~::o-tRNA^opt^                                                                                                                                                   this study

Ap^R^, Cm^R^, Km^R^, Sp^R^, and Tet^R^ are ampicillin, chloramphenicol, kanamycin, spectinomycin, and tetracycline resistance, respectively.

Growth Measurement {#sec3.2}
------------------

Overnight cultures of *rEc.E13* and *rEc.E13.ΔprfA* strains grown in Luria--Bertani (LB)^[@ref47]^ at 250 rpm at 34 °C were diluted to an OD of 0.05 at 600 nm in LB and 2xYTPG media (16 g/L tryptone, 10 g/L yeast extract, 5 g/L NaCl, 7 g/L K~2~HPO~4~, 3 g/L KH~2~PO~4~, and 18 g/L glucose; adjusted pH to 7.1 with KOH). 100 μL of the diluted cultures was added in 96-well polystyrene plates (Costar 3370; Corning Incorporated, Corning, NY). OD~600~ was measured at 15 min intervals for 15 h at 34 °C with fast shaking mode on a Synergy2 plate reader (Biotek, Winooski, VT). Growth data of each strain was obtained from ten replicate wells with two independent cultures. BL21(DE3) strains containing pY71-pPaFRS or pY71-pAcFRS were incubated at 37 °C in LB with different concentrations (0 mM, 0.01 mM, 0.1 mM, or 1 mM) of isopropyl-β-D-thiogalactopyranoside (IPTG) (Sigma, St. Louis, MO) in 96 well plates. Growth data of each strain was obtained from six replicate wells with three independent cultures.

Cell Extract Preparation {#sec3.3}
------------------------

*E. coli* cell extracts were prepared from *rEc.E13* and *rEc.E13.ΔprfA* strains containing pDULE-o-tRNA. Cells were grown in a BIOSTAT C-plus fermentor (Sartorious AG, Goettingen, Germany) to OD at 600 nm of 3.0 in 10 L of 2xYTPG media at 34 °C. Cells were pelleted by centrifuging for 15 min at 6000 × g at 4 °C, washed twice with cold S30 buffer (10 mM tris-acetate pH 8.2, 14 mM magnesium acetate, 60 mM potassium acetate, 1 mM dithiothreitol),^[@ref48]^ and stored at −80 °C. Thawed cells were suspended in 1 mL of S30 buffer per gram cells and lysed in EmulsiFlex-C3 homogenizer (Avestin, Manheim, Germany) with a single pass at pressure of 20 000 to 25 000 psi. Cell debris and insoluble components were removed by two rounds of centrifugation for 30 min at 30 000 × *g* at 4 °C. The clarified samples were incubated for 80 min at 120 rpm at 37 °C to optimize the extract activity and centrifuged for 15 min at 15 000 × *g* at 4 °C. The supernatant was flash-frozen using liquid nitrogen and stored at −80 °C until use. Total protein concentration of the extracts was approximately 50 mg/mL, as measured by Quick-Start Bradford protein assay kits (Bio-Rad, Hercules, CA).

Preparation of NSAAs {#sec3.4}
--------------------

pPaF and pAcF were used to examine NSAA incorporation. pPaF was synthesized as described previously,^[@ref49]^ and pAcF was purchased through Chem-Impex International (PN 24756; Wood Dale, IL). Stock solutions (500 mM) of pPaF and pAcF in 0.5 N NaOH were prepared. Working concentration of pPaF or pAcF was 2 mM in CFPS reaction. Adding the same volume of 0.5 N NaOH to CFPS reactions did not affect protein synthesis efficiency.

Plasmid Construction {#sec3.5}
--------------------

Amber codons were introduced at the corresponding positions of E132, D190, N212 in sfGFP using inverse PCR with TAG insertion primers ([Supporting Information Table S1](#notes-2){ref-type="notes"}) on pY71-sfGFP plasmid. PCR was performed using Phusion High-Fidelity DNA polymerase (New England Biolabs, Ipswich, MA) at 98 °C for 30 s, with 30 cycles of 98 °C for 10 s, 60 °C for 30 s, and 72 °C for 3 min, and a final extension of 72 °C for 5 min followed by ligation and DpnI digestion. The constructed plasmids were electroporated in to BL21(DE3) competent cells. In order to introduce two TAGs in *sfGFP*, an amber codon was added at the codon corresponding to N212 on pY71-sfGFP-T216amb, resulting in pY71-sfGFP-2amb. sfGFP with five amber sites (corresponding to positions D36, K101, E132, D190, and E213) or ten amber sites (corresponding to positions D36, K101, D102, E132, D133, K140, D190, V193, E213, and D218) was synthesized through GenScript (Piscataway, NJ) and cloned into pY71 vector using *NdeI* and *Sal*I restriction sites to construct pY71-sfGFP-5amb and pY71-sfGFP-10amb. pAcFRS gene was amplified from pEVOL-pAcF using pAcF-NdeI-f and pAcF-*Sal*I-r primers ([Supporting Information Table S1](#notes-2){ref-type="notes"}) and cloned into pY71 vector using *NdeI* and *Sal*I sites to construct pY71-pAcFRS. All constructs were confirmed by DNA sequencing using pY71-f and pY71-r primers ([Supporting Information Table S1](#notes-2){ref-type="notes"}).

o-tRNA Synthetase Purification {#sec3.6}
------------------------------

o-tRNA synthetases were purified as described previously^[@ref23]^ with modifications. BL21(DE3) harboring pY71-pPaFRS or pY71-pAcFRS was grown in 1 L LB to OD at 600 nm of 1.0 at 250 rpm and 37 °C. pPaFRS and pAcFRS were produced by adding 0.2 mM IPTG for 3 h. Cells were harvested at 5000 × *g* for 30 min at 4 °C, washed with S30 buffer, and stored at −80 °C. The frozen cell pellet was thawed in loading buffer (300 mM NaCl, 10 mM imidazole, 50 mM NaH~2~PO~4~, 5 mM Tris--HCl, pH 8.0) and lysed using a homogenizer at 20 000--25 000 psi. After clarification by centrifuging at 16 000 × *g* at 4 °C for 30 min, the supernatant was loaded into a 1 mL Ni-NTA column using a BioLogic DuoFlow FPLC system (Bio-Rad, Hercules, CA). The column was washed with wash buffer (300 mM NaCl, 50 mM imidazole, 50 mM NaH~2~PO~4~, 5 mM Tris--HCl, pH 8.0), and His-tagged proteins were eluted with 250 mM imidazole in wash buffer. The eluent was dialyzed three times for 2 h each using 6000--8000 MWCO dialysis tubing (Spectrum, New Brunswick, NJ) with 10 volumes of phosphate buffer (pH 7.4) for pPaFRS^[@ref23]^ and the aaRS-buffer (20 mM Tris-HCl pH 8.0, 150 mM KCl, 15 mM MgCl~2~, and 5 mM β-mercaptoethanol) for pAcFRS.^[@ref50]^ The proteins were concentrated using Amicon Ultracel YM-3 centrifugal filter (Millipore, Billerica, MA). Protein purity was confirmed by 4--12% NuPAGE SDS-PAGE (Life Technologies, Grand Island, NY). Concentrations were determined by Quick-Start Bradford protein assay kit (Bio-Rad, Hercules, CA).

CFPS Reaction {#sec3.7}
-------------

CFPS reactions were performed testing for incorporation of pPaF and pAcF using a modified PANOx-SP system.^[@ref17]^ Briefly, 15 uL of CFPS reaction in a 1.5 mL microcentrifuge tube was prepared by mixing the following components: 1.2 mM ATP; 0.85 mM each of GTP, UTP, and CTP; 34.0 μg/mL folinic acid; 170.0 μg/mL of *E. coli* tRNA mixture; 13.3 μg/mL plasmid; 100 μg/mL T7 RNA polymerase; 2 mM each of 20 standard amino acids; 0.33 mM nicotinamide adenine dinucleotide (NAD); 0.27 mM coenzyme-A (CoA); 1.5 mM spermidine; 1 mM putrescine; 4 mM sodium oxalate; 130 mM potassium glutamate; 10 mM ammonium glutamate; 12 mM magnesium glutamate; 33 mM phosphoenolpyruvate (PEP); 2 mM pPaF or pAcF; 0.1 to 2 mg/mL pPaFRS or pAcFRS and 27% v/v of cell extract. The sample was incubated for 20 h at 30 °C unless noted otherwise.

Quantification of the Synthesized sfGFP {#sec3.8}
---------------------------------------

Total and soluble protein yields were quantified by determining radioactive ^14^C-Leu incorporation using trichloroacetic acid (TCA).^[@ref48]^ Radioactivity of TCA-precipitated samples was measured using liquid scintillation counting (MicroBeta2, PerkinElmer, Waltham, MA). Active sfGFP protein yields were quantified by measuring fluorescence. Two microliters of CFPS reaction was added in the middle of the flat bottom of 96-well half area black plates (Costar 3694; Corning Incorporated, Corning, NY). sfGFP was excited at 485 nm while measuring emission at 528 nm with a 510 nm cutoff filter. The fluorescence of sfGFP was converted to concentration (μg/mL) according to a standard curve ([Supporting Information Figure S4](#notes-2){ref-type="notes"}).

Autoradiography Analysis {#sec3.9}
------------------------

Radioactive ^35^S-Met was added in CFPS reactions. 2.5 μL of each reaction was loaded on 4--12% NuPAGE SDS-PAGE gel after denaturing the sample. The gel was soaked in Gel Drying Solution (Bio-Rad, Hercules, CA) for 30 min, fixed with cellophane films, dried applying heat for 1 h in GelAir Dryer (Bio-Rad, Hercules, CA), and exposed overnight on Storage Phosphor Screen (GE Healthcare Biosciences, Pittsburgh, PA). Autoradiogram was scanned using Storm Imager (GE Healthcare Biosciences, Pittsburgh, PA) and analyzed using Quantity One software (Bio-Rad, Hercules, CA).

Construction of Linear DNA Templates for Expressing o-tRNA {#sec3.10}
----------------------------------------------------------

DNA oligomers of o-tRNA and optimized o-tRNA bearing a T7 promoter with or without hammerhead ribozyme (Figure [5](#fig5){ref-type="fig"}c), were synthesized via gBlocks (Integrated DNA technologies, Coralville, IA). DNA sequences of o-tRNA and optimized o-tRNA (Figure [5](#fig5){ref-type="fig"}c) were obtained from plasmid pDULE-o-tRNA^[@ref24]^ and pEVOL-pAcF,^[@ref35]^ respectively. The hammerhead ribozyme sequence (Figure [5](#fig5){ref-type="fig"}c) was added between the T7-promoter and o-tRNA sequence.^[@ref22]^ The gBlock fragments were amplified using T7-PCRamp-f and T7-PCRamp-r primers ([Supporting Information Table S1](#notes-2){ref-type="notes"}), cloned into pY71 plasmid using *Bgl*II and *Sal*I restriction sites, and confirmed by DNA sequencing using tRNA-seq-f and tRNA-seq-r primers ([Supporting Information Table S1](#notes-2){ref-type="notes"}). Linear DNA templates of original or optimized o-tRNA were generated by PCR amplification using T7tRNA500-f and T7tRNA-r or T7tRNAopt-r primers ([Supporting Information Table S1](#notes-2){ref-type="notes"}).

CFPS Using PURE System {#sec3.11}
----------------------

NSAA incorporation was examined in the PURE system using PURExpress ΔRF123 Kit (New England Biolabs, Ipswich, MA). The reaction components of PURExpress with and without RF1 were mixed with 5 μg/mL sfGFP plasmids, 2 mM pPaF, 0.5 mg/mL pPaFRS, and 4.5 ng/μL linear DNA template of optimized o-tRNA in a 10 μL reaction. The reaction was incubated for 20 h at 30 °C.

Full-length sfGFP Purification {#sec3.12}
------------------------------

To confirm pPaF incorporation at corresponding amber codon positions, mass spectrometry analysis was performed with purified sfGFP with NSAA incorporated. Full-length sfGFP was purified using C-terminal strep-tags and 0.2 mL gravity-flow Strep-Tactin Sepharose mini-columns (IBA GmbH, Gottingen, Germany). Eluted protein samples were concentrated using Microcon centrifugal filter columns YM-10 (Millipore, Billerica, MA).

Mass Spectrometry {#sec3.13}
-----------------

The semipurified protein was analyzed by nanocapillary LC-MS using a 100 mm × 75 μm ID PLRP-S column in-line with an Orbitrap Elite (ThermoFisher, Waltham, MA). All MS methods included the following events: (1) FT scan, *m*/*z* 400--2000, 120 000 resolving power and (2) data-dependent MS/MS on the top 2 peaks in each spectrum from scan event 1 using higher-energy collisional dissociation (HCD) with normalized collision energy of 25, isolation width 50 *m*/*z*, and detection of ions with resolving power of 60 000. All data were analyzed using QualBrowser, part of the Xcalibur software packaged with the ThermoFisher Orbitrap Elite.

This information is available free of charge via the Internet at <http://pubs.acs.org>.
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